Sight Sciences Inc. (NASDAQ: SGHT) secured a court order that upholds a jury verdict finding Alcon Inc. willfully infringed three of its patents related to glaucoma treatment devices. The U.S. District Court for the District of Delaware entered the order on March 27, 2026.

The court awarded Sight Sciences $34 million in monetary damages, comprising $5.5 million in lost profits and $28.5 million in royalty damages for Alcon's Hydrus Microstent sales from commercial launch through the jury verdict. The judgment also includes an ongoing royalty of 10% of Hydrus revenue through November 10, 2028, when Sight Sciences' last asserted patent expires.

The case, originally filed on September 16, 2021, involved three Sight Sciences patents: U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The jury found that Alcon's sale of the Hydrus Microstent infringed all three patents.

A final judgment is expected after supplemental damages and pre-judgment interest calculations are completed based on additional financial data from Alcon. The judgment remains subject to appeal by Alcon and may be affected by ex parte reexamination proceedings Alcon filed with the U.S. Patent and Trademark Office.

"We are pleased with the results of the ruling and the recognition of our strong intellectual property portfolio in interventional glaucoma," said Paul Badawi, co-founder and chief executive officer of Sight Sciences.

Sight Sciences expects to record a $5.4 million success fee to operating expenses, payable to law firm Cooley LLP, which represented the company in the litigation. The company plans to exclude this fee from non-GAAP adjusted operating expenses.